GlassScriptPhysician profile
Mary Lowe
NPI 1285214957
$3,074.25
in general payments reported to CMS, 2019-2025
23 companies · $2,372 in 2025
The $2,372 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $43.14 · 2024: $659 · 2025: $2,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $309.53 | 2024-2025 | |
| Corium, LLC | $249.46 | 2024-2025 | Azstarys |
| Pfizer INC. | $217.55 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.77 | 2024-2025 | Caplyta |
| Dexcom, INC. | $188.99 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Glaxosmithkline, LLC. | $178.53 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $168.50 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $166.80 | 2024-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $140.35 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $133.90 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $97.36 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $89.69 | 2025 | Auvelity |
| Astellas Pharma US INC | $82.85 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $74.06 | 2025 | Spravato |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $70.84 | 2025 | Rexulti |
| Amgen INC. | $67.90 | 2025 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $66.96 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.06 | 2024-2025 | Jardiance |
| Gilead Sciences, INC. | $44.77 | 2023-2024 | Epclusa |
| Lundbeck LLC | $24.86 | 2025 | Vyepti |
| Evofem Biosciences, INC. | $23.12 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.32 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.